StockData
Integrated BioPharma Inc logo

Integrated BioPharma Inc (INBP) stock

INBPOTCPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.18+0.00 (0.00%)

Close on Oct 19, 2026Market cap $5.59MP/E –Yield –

Integrated BioPharma operating margin

Operating margin is operating income as a percentage of revenue.

Integrated BioPharma's operating margin for the twelve months ending Jun 30, 2026 was -6.2%. For fiscal 2026 it was -6.2%, against 3.7% the year before. The highest annual figure on record is 9.1% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2026Jun 30, 2026-6.2%−9.9
FY2025Jun 30, 20253.7%+3.2
FY2024Jun 30, 20240.5%+0.3
FY2023Jun 30, 20230.2%−4.6
FY2022Jun 30, 20224.9%−4.2
FY2021Jun 30, 20219.1%+2.9
FY2020Jun 30, 20206.2%+0.8
FY2019Jun 30, 20195.4%+1.5
FY2018Jun 30, 20183.9%−2.9
FY2017Jun 30, 20176.8%+1.8
FY2016Jun 30, 20165.0%+2.5
FY2015Jun 30, 20152.5%−1.5
FY2014Jun 30, 20144.0%+0.7
FY2013Jun 30, 20133.3%+4.7
FY2012Jun 30, 2012-1.4%−0.5
FY2011Jun 30, 2011-0.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jun 30, 2026-8.9%−13.0
Q3 FY2026CQ1 2026Mar 31, 2026-10.7%−16.0
Q2 FY2026CQ4 2025Dec 31, 2025-8.1%−9.7
Q1 FY2026CQ3 2025Sep 30, 20251.3%−2.3
Q4 FY2025CQ2 2025Jun 30, 20254.2%+1.0
Q3 FY2025CQ1 2025Mar 31, 20255.3%+2.6
Q2 FY2025CQ4 2024Dec 31, 20241.6%+5.5
Q1 FY2025CQ3 2024Sep 30, 20243.6%+4.0
Q4 FY2024CQ2 2024Jun 30, 20243.2%+2.5
Q3 FY2024CQ1 2024Mar 31, 20242.7%+2.4
Q2 FY2024CQ4 2023Dec 31, 2023-3.9%−3.7
Q1 FY2024CQ3 2023Sep 30, 2023-0.4%−0.7
Q4 FY2023CQ2 2023Jun 30, 20230.6%−2.7
Q3 FY2023CQ1 2023Mar 31, 20230.3%−6.0
Q2 FY2023CQ4 2022Dec 31, 2022-0.3%−5.3
Q1 FY2023CQ3 2022Sep 30, 20220.2%−4.3
Q4 FY2022CQ2 2022Jun 30, 20223.3%−4.4
Q3 FY2022CQ1 2022Mar 31, 20226.3%−3.7
Q2 FY2022CQ4 2021Dec 31, 20215.0%−3.7
Q1 FY2022CQ3 2021Sep 30, 20214.6%−5.4
Q4 FY2021CQ2 2021Jun 30, 20217.7%+3.1
Q3 FY2021CQ1 2021Mar 31, 202110.1%+3.0
Q2 FY2021CQ4 2020Dec 31, 20208.7%+0.2
Q1 FY2021CQ3 2020Sep 30, 20209.9%+5.8
Q4 FY2020CQ2 2020Jun 30, 20204.6%+0.3
Q3 FY2020CQ1 2020Mar 31, 20207.0%−1.7
Q2 FY2020CQ4 2019Dec 31, 20198.5%+4.4
Q1 FY2020CQ3 2019Sep 30, 20194.2%+0.2
Q4 FY2019CQ2 2019Jun 30, 20194.2%−0.7
Q3 FY2019CQ1 2019Mar 31, 20198.8%+2.5
Q2 FY2019CQ4 2018Dec 31, 20184.1%+2.2
Q1 FY2019CQ3 2018Sep 30, 20183.9%+1.8
Q4 FY2018CQ2 2018Jun 30, 20185.0%−2.4
Q3 FY2018CQ1 2018Mar 31, 20186.2%+2.2
Q2 FY2018CQ4 2017Dec 31, 20171.8%−2.8
Q1 FY2018CQ3 2017Sep 30, 20172.2%−8.6
Q4 FY2017CQ2 2017Jun 30, 20177.4%–
Q3 FY2017CQ1 2017Mar 31, 20174.0%–
Q2 FY2017CQ4 2016Dec 31, 20164.6%–
Q1 FY2017CQ3 2016Sep 30, 201610.7%–

More Integrated BioPharma figures

See a number that looks wrong?